Polar Asset Management Partners Inc. Has $1.62 Million Position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Polar Asset Management Partners Inc. lessened its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 41.0% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 5,900 shares of the biopharmaceutical company’s stock after selling 4,100 shares during the period. Polar Asset Management Partners Inc.’s holdings in Alnylam Pharmaceuticals were worth $1,623,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Diversified Trust Co acquired a new stake in shares of Alnylam Pharmaceuticals during the 2nd quarter worth about $1,210,000. Los Angeles Capital Management LLC boosted its holdings in shares of Alnylam Pharmaceuticals by 11,433.4% in the 3rd quarter. Los Angeles Capital Management LLC now owns 137,017 shares of the biopharmaceutical company’s stock worth $37,684,000 after acquiring an additional 135,829 shares in the last quarter. Breakwater Capital Group bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth approximately $249,000. Sanctuary Advisors LLC acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at $578,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its stake in Alnylam Pharmaceuticals by 22.4% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 73,320 shares of the biopharmaceutical company’s stock worth $20,165,000 after purchasing an additional 13,422 shares in the last quarter. Institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CMO Pushkal Garg sold 1,682 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $422,148.36. Following the completion of the transaction, the chief marketing officer now owns 17,457 shares in the company, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Tolga Tanguler sold 1,469 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total value of $368,689.62. Following the completion of the sale, the executive vice president now directly owns 13,191 shares in the company, valued at approximately $3,310,677.18. This represents a 10.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 8,370 shares of company stock valued at $2,100,703 over the last three months. Company insiders own 1.50% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. William Blair restated an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Tuesday, November 19th. HC Wainwright reiterated a “buy” rating and set a $400.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Piper Sandler reissued an “overweight” rating and issued a $296.00 price target on shares of Alnylam Pharmaceuticals in a report on Monday, November 18th. JPMorgan Chase & Co. upped their price objective on Alnylam Pharmaceuticals from $248.00 to $280.00 and gave the stock a “neutral” rating in a report on Monday, August 26th. Finally, Chardan Capital reissued a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have issued a hold rating and eighteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $298.09.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY opened at $251.81 on Friday. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The stock has a market cap of $32.48 billion, a price-to-earnings ratio of -96.11 and a beta of 0.32. The business has a 50 day simple moving average of $269.49 and a 200 day simple moving average of $243.89. Alnylam Pharmaceuticals, Inc. has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million for the quarter, compared to analyst estimates of $532.91 million. The firm’s revenue for the quarter was down 33.3% compared to the same quarter last year. During the same quarter last year, the firm posted $1.15 EPS. Analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.